Literature DB >> 15256375

N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Dahai Wang1, Oscar A Carretero, Xiao-Yi Yang, Nour-Eddine Rhaleb, Yun-He Liu, Tang-Dong Liao, Xiao-Ping Yang.   

Abstract

N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a natural inhibitor of pluripotent hematopoietic stem cell proliferation, has been suggested as capable of promoting an angiogenic response. We studied whether Ac-SDKP stimulates endothelial cell proliferation, migration, and tube formation; enhances angiogenic response in the rat cornea after implantation of a tumor spheroid; and increases capillary density in rat hearts with myocardial infarction (MI). In vitro, an immortal BALB/c mouse aortic endothelial 22106 cell line was used to determine the effects of Ac-SDKP on endothelial cell proliferation and migration and tube formation. In vivo, a 9L-gliosarcoma cell spheroid (250-300 microm in diameter) was implanted in the rat cornea and vehicle or Ac-SDKP (800 microg.kg(-1).day(-1) ip) infused via osmotic minipump. Myocardial capillary density was studied in rats with MI given either vehicle or Ac-SDKP. We found that Ac-SDKP 1) stimulated endothelial cell proliferation and migration and tube formation in a dose-dependent manner, 2) enhanced corneal neovascularization, and 3) increased myocardial capillary density. Endothelial cell proliferation and angiogenesis stimulated by Ac-SDKP could be beneficial in cardiovascular diseases such as hypertension and MI. Furthermore, because Ac-SDKP is mainly cleaved by ACE, it may partially mediate the cardioprotective effect of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256375      PMCID: PMC6824423          DOI: 10.1152/ajpheart.00592.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  42 in total

1.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Authors:  O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.

Authors:  A E Bogden; P Carde; E D de Paillette; J P Moreau; M Tubiana; E Frindel
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

3.  Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.

Authors:  P Gohlke; I Kuwer; A Schnell; K Amann; G Mall; T Unger
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

Review 4.  Molecular mechanisms of tumor angiogenesis and tumor progression.

Authors:  U Cavallaro; G Christofori
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture.

Authors:  J Wdzieczak-Bakala; M P Fache; M Lenfant; E Frindel; F Sainteny
Journal:  Leukemia       Date:  1990-03       Impact factor: 11.528

6.  In vivo effect of the tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro, on the G1-S transition of rat hepatocytes.

Authors:  M N Lombard; D Sotty; J Wdzieczak-Bakala; M Lenfant
Journal:  Cell Tissue Kinet       Date:  1990-03

7.  Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model.

Authors:  V Koutrafouri; L Leondiadis; K Avgoustakis; E Livaniou; J Czarnecki; D S Ithakissios; G P Evangelatos
Journal:  Biochim Biophys Acta       Date:  2001-11-07

8.  Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  M Azizi; A Rousseau; E Ezan; T T Guyene; S Michelet; J M Grognet; M Lenfant; P Corvol; J Ménard
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

9.  In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation.

Authors:  T Watanabe; G S Brown; L S Kelsey; Y Yan; J D Jackson; C Ewel; A Kessinger; J E Talmadge
Journal:  Exp Hematol       Date:  1996-05       Impact factor: 3.084

10.  Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; David R Brigstock; Nancy Oja-Tebbe; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2003-10-27       Impact factor: 10.190

View more
  28 in total

Review 1.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

2.  MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.

Authors:  G Ding; Z Zhang; M Chopp; L Li; L Zhang; Q Li; M Wei; Q Jiang
Journal:  Neuroscience       Date:  2014-04-24       Impact factor: 3.590

3.  Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  Yanlu Zhang; Zheng Gang Zhang; Michael Chopp; Yuling Meng; Li Zhang; Asim Mahmood; Ye Xiong
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

4.  Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension.

Authors:  Germán E González; N-E Rhaleb; Martin A D'Ambrosio; Pablo Nakagawa; Tang-Dong Liao; Edward L Peterson; Pablo Leung; Xiangguo Dai; Branislava Janic; Yun-He Liu; Xiao-Ping Yang; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-08-05       Impact factor: 4.733

Review 5.  The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Authors:  Takako Nagai; Kyoko Nitta; Megumi Kanasaki; Daisuke Koya; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2014-07-01       Impact factor: 2.801

Review 6.  Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

Authors:  Kamal M Kassem; Sonal Vaid; Hongmei Peng; Sarah Sarkar; Nour-Eddine Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  2019-03-09       Impact factor: 2.273

7.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

8.  The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase.

Authors:  Nitin Kumar; Pablo Nakagawa; Branislava Janic; Cesar A Romero; Morel E Worou; Sumit R Monu; Edward L Peterson; Jiajiu Shaw; Frederick Valeriote; Elimelda M Ongeri; Jean-Marie V Niyitegeka; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-09

9.  N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.

Authors:  Yun-He Liu; Martin D'Ambrosio; Tang-dong Liao; Hongmei Peng; Nour-Eddine Rhaleb; Umesh Sharma; Sabine André; Hans-J Gabius; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-19       Impact factor: 4.733

10.  Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.

Authors:  Umesh Sharma; Nour-Eddine Rhaleb; Saraswati Pokharel; Pamela Harding; Saman Rasoul; Hongmei Peng; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-04       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.